Holen Sie sich die Stockscreener-App
110.43
1.53%
1.76
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$108.67
Offen:
$110.78
24-Stunden-Volumen:
1.71M
Relative Volume:
0.36
Marktkapitalisierung:
$482.80B
Einnahmen:
$39.36B
Nettoeinkommen (Verlust:
$13.79B
KGV:
45.87
EPS:
2.4077
Netto-Cashflow:
$9.83B
1W Leistung:
+3.96%
1M Leistung:
-1.44%
6M Leistung:
-18.65%
1J Leistung:
+9.89%
1-Tages-Spanne:
$109.96
$110.88
1-Wochen-Bereich:
$104.96
$110.88
52-Wochen-Spanne:
$94.73
$148.15
Novo Nordisk Adr Stock (NVO) Company Profile
Vergleichen Sie NVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
110.40 | 482.80B | 39.36B | 13.79B | 9.83B | 3.086 |
|
LLY
Lilly Eli Co
|
810.48 | 755.90B | 40.86B | 8.37B | -2.28B | 9.25 |
|
JNJ
Johnson Johnson
|
153.62 | 353.35B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
182.90 | 319.48B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
102.29 | 254.41B | 63.17B | 12.15B | 14.84B | 4.77 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Why Novo Nordisk A/S (NVO) Is the Best ADR Stock to Invest in? - Yahoo Finance
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? - The Motley Fool
12 Best ADR Stocks To Invest In According to Analysts - Insider Monkey
NVO Stock Quote Price and Forecast - CNN
European Equities Traded in the US as American Depositary Decline in Tuesday Trading - MSN
Novo Nordisk ADR (NYSE: NVO) Could Fell Another -55.9% - Stocks Register
Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets
10 Biggest Biotechnology Companies - Investopedia
Biopharma Stock Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges - Morningstar
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View - Yahoo Finance
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading - MSN
Novo Nordisk ADR earnings beat by $5.24, revenue topped estimates - Investing.com Australia
Thanks To Wall Street, Novo Nordisk Stock Is Now A Buy - Barchart
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
India Subcutaneous Drug Delivery Devices Market Size & Outlook, 2030 - Grand View Research
Why this money manager sees FirstService, Novo Nordisk and Microsoft as good long-term holdings - The Globe and Mail
NVO: 3 European Stocks to Buy as the Region Recovers - StockNews.com
NVO’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Market cap of Novo Nordisk ADR [NVO] reaches 391.26B – now what? - The DBT News
Analyzing Novo Nordisk ADR (NVO) After Recent Trading Activity - Knox Daily
Monitoring Melco Resorts & Entertainment Ltd ADR (MLCO) after recent insider movements - Knox Daily
Weekly Upgrades and Downgrades - InvestorPlace
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):